Skip to content
EmergingResearch compoundReference only

Doliracetam

Little-known experimental racetam from a 1982 patent; practically no research data exists on it.

NootropicRacetamRacetamMemoryAcetylcholineGlutamate

Pharmacology

ClassRacetam · Memory
Primary targetCholinergic transmission (proposed, weak modulation)
Targets3 receptor targets
Half-lifeN/A
OnsetN/A
EvidenceReference only
Affected systemsAcetylcholineGlutamate

Contents

DETAILED OVERVIEW

What is Doliracetam?

Doliracetam is an experimental compound grouped with the racetams. It was first described in a 1982 patent. It is not approved as a medicine anywhere, and it is not sold as a dietary supplement either. It is one of the most poorly documented racetams, so today it is mostly a curiosity from the history of science.

Improved memory and anti-seizure effects have been suggested for it, but these are only patent claims: independent research has not confirmed them, and practically no studies have been done on humans. A mechanism of action has never been established, and the scientific literature contains no animal or human study dedicated to it. Its side effects and interactions with medicines are unknown. It should be avoided in pregnancy and breastfeeding, because there are no safety data.

Mechanism

Uncharacterized (patent-claimed neuroanabolic)

Half-life

N/A

Onset

N/A

Legal status

Unapproved, unmarketed; reference material only

Receptor profile

  • Cholinergic transmissionWeak
  • AMPA glutamate receptorsWeak
  • Neuronal plasticityWeak

Safety

Side effects, stop signs, contraindications

Side effects · 3

  • With virtually no human data, the side-effect profile is unknown; racetam-like effects such as headache are plausible but unconfirmed
  • Theoretical choline-depletion headache, as with other racetams; a choline source may help in principle, but this is unproven
  • Unknown long-term safety: never marketed and with no clinical development on record

Contraindications · 3

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Not a medicine: human clinical trials have not established its safety, any use is experimental
  • Unknown drug interactions: the mechanism is uncharacterized, so co-administration risk cannot be estimated

Related Nootropics

Same therapeutic category

FAQ

FAQ

Doliracetam is an obscure experimental compound first described in a 1982 pharmaceutical patent, which claimed it might help with memory and have anti-seizure properties. Those claims come only from the patent itself, and there's essentially no human testing to back them up. Today it's mostly a historical and structural curiosity rather than something with an established practical use.

Telegram

Have a question about Doliracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC16H14N2O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.